HSBC upgraded Gilead Sciences stock, citing pessimistic consensus.
1 report, 1 independent
Updated Jul 6
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
HSBC upgraded Gilead Sciences stock, citing pessimistic consensus.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
HSBC
British multinational bank
-
Gilead Sciences
American company
- Required regulatory filings regarding institutional holdings were made by Gilead Sciences, Inc. with the Securities and Exchange Commission on June 11, 2026.
- A pilot program is underway involving the federal government, Benue State, and Gilead Sciences, with the state participating in the drug supply management.
Related events
- Gilead Sciences acquired Arcellx and presented priorities at a Wells Fargo conference, while also discussing submissions with the FDA and CDC.
- HSBC provided a rating upgrade on MGM Resorts International stock, with market consensus suggesting a 'Moderate Buy' rating.
- Morgan Stanley provided research notes and an Overweight rating on Gilead Sciences stock on September 20, 2026.
- GSK and EXEL are developing treatments for PBC, and the FDA granted accelerated approval to Gilead Sciences for related therapies.
- Gilead Sciences and Grifols traded on the NASDAQ stock exchange on September 8, 2026.